UBS Group AG Has $2.14 Million Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

UBS Group AG decreased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 92.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,047 shares of the specialty pharmaceutical company’s stock after selling 497,076 shares during the period. UBS Group AG’s holdings in Supernus Pharmaceuticals were worth $2,139,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SUPN. Rubric Capital Management LP acquired a new position in Supernus Pharmaceuticals during the 2nd quarter worth about $21,908,000. Woodline Partners LP lifted its position in Supernus Pharmaceuticals by 63.5% during the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares in the last quarter. Bank of America Corp DE lifted its position in Supernus Pharmaceuticals by 67.1% during the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after buying an additional 338,584 shares in the last quarter. Sofinnova Investments Inc. lifted its position in Supernus Pharmaceuticals by 53.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock worth $25,192,000 after buying an additional 278,575 shares in the last quarter. Finally, Aberdeen Group plc acquired a new position in Supernus Pharmaceuticals during the 4th quarter worth about $13,497,000.

Insiders Place Their Bets

In related news, VP Padmanabh P. Bhatt sold 7,250 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $49.60, for a total transaction of $359,600.00. Following the completion of the sale, the vice president directly owned 17,044 shares of the company’s stock, valued at approximately $845,382.40. This represents a 29.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Frederick M. Hudson sold 5,369 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $50.61, for a total value of $271,725.09. Following the sale, the director directly owned 60,413 shares of the company’s stock, valued at approximately $3,057,501.93. The trade was a 8.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 116,406 shares of company stock valued at $5,911,086 in the last quarter. 8.80% of the stock is owned by company insiders.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $46.64 on Thursday. The stock has a market cap of $2.71 billion, a PE ratio of -91.45, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57. The stock has a 50-day moving average of $49.84 and a 200-day moving average of $49.58. Supernus Pharmaceuticals, Inc. has a one year low of $30.83 and a one year high of $59.68.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SUPN. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 23rd. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Finally, Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $62.17.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.